Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

Compelling evidence indicates Type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune effector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the con...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindorfer, Margaret A., Wiestner, Adrian, Zent, Clive S., Taylor, Ronald P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489759/
https://www.ncbi.nlm.nih.gov/pubmed/23162771
http://dx.doi.org/10.4161/onci.20368
_version_ 1782248776622145536
author Lindorfer, Margaret A.
Wiestner, Adrian
Zent, Clive S.
Taylor, Ronald P.
author_facet Lindorfer, Margaret A.
Wiestner, Adrian
Zent, Clive S.
Taylor, Ronald P.
author_sort Lindorfer, Margaret A.
collection PubMed
description Compelling evidence indicates Type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune effector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the conclusion that lower doses, given frequently, may be far more effective.
format Online
Article
Text
id pubmed-3489759
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-34897592012-11-16 Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies? Lindorfer, Margaret A. Wiestner, Adrian Zent, Clive S. Taylor, Ronald P. Oncoimmunology Author's View Compelling evidence indicates Type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune effector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the conclusion that lower doses, given frequently, may be far more effective. Landes Bioscience 2012-09-01 /pmc/articles/PMC3489759/ /pubmed/23162771 http://dx.doi.org/10.4161/onci.20368 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Lindorfer, Margaret A.
Wiestner, Adrian
Zent, Clive S.
Taylor, Ronald P.
Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?
title Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?
title_full Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?
title_fullStr Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?
title_full_unstemmed Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?
title_short Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?
title_sort monoclonal antibody (mab)-based cancer therapy: is it time to reevaluate dosing strategies?
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489759/
https://www.ncbi.nlm.nih.gov/pubmed/23162771
http://dx.doi.org/10.4161/onci.20368
work_keys_str_mv AT lindorfermargareta monoclonalantibodymabbasedcancertherapyisittimetoreevaluatedosingstrategies
AT wiestneradrian monoclonalantibodymabbasedcancertherapyisittimetoreevaluatedosingstrategies
AT zentclives monoclonalantibodymabbasedcancertherapyisittimetoreevaluatedosingstrategies
AT taylorronaldp monoclonalantibodymabbasedcancertherapyisittimetoreevaluatedosingstrategies

Ejemplares similares